Concepedia

Real-world safety experience of tevagrastim/ratiograstim/biograstim and tbo-filgrastim, short-acting recombinant human granulocyte colony-stimulating factors

Camille N. Abboud, Nicole Lang, Henry C. Fung, Andreas Lammerich, Anton Buchner, Patrick Liu, U. Mueller, Ruth Pettengell, Ingo Diel, Hartmut Link,

Supportive Care in Cancer · 2018 · 19 citations · 3 references

DOIFull text

Open access

Concepts

References

3

XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy

Auro del Giglio, Alexandru Eniu, Doina Elena Ganea-Motan et al. · BMC Cancer · 2008 · 105 citations · Full text

, , +14

XM02, the First Biosimilar G-CSF, is Safe and Effective in Reducing the Duration of Severe Neutropenia and Incidence of Febrile Neutropenia in Patients with Small Cell or Non-small Cell Lung Cancer Receiving Platinum-Based Chemotherapy

U. Gatzemeier, Tudor–Eliade Ciuleanu, Mircea Dediu et al. · Journal of Thoracic Oncology · 2009 · 87 citations · Full text

, , +12

XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy

Andreas Engert, Laimonas Griškevičius, Y. Zyuzgin et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2009 · 75 citations

, , +16